scholarly journals Effectiveness of randomized control trial of mobile phone messages on control of fasting blood glucose in patients with type-2 diabetes mellitus in a Northern State of India

2018 ◽  
Vol 62 (3) ◽  
pp. 224 ◽  
Author(s):  
Dinesh Kumar ◽  
Sujeet Raina ◽  
SatyaBhushan Sharma ◽  
SunilKumar Raina ◽  
AshokKumar Bhardwaj
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Mobile Phone ◽  
Randomized Control Trial ◽  
Fasting Blood Glucose ◽  
Randomized Control ◽  
Northern State

Epigenetic modulation of autophagy genes linked to diabetic nephropathy by administration of isorhamnetin in Type 2 diabetes mellitus rats

Epigenomics ◽  
2021 ◽  
Author(s):  
Marwa Matboli ◽  
Doaa Ibrahim ◽  
Amany H Hasanin ◽  
Mohamed Kamel Hassan ◽  
Eman K Habib ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Light And Electron Microscopy ◽  
Lipid Profiles ◽  
Mirna Regulation ◽  
Protein Levels

Aim: To assess isorhamnetin efficacy for diabetic kidney disease in a Type 2 diabetes mellitus rat model, through investigating its effect at the epigenetic, mRNA and protein levels. Materials & methods: Type 2 diabetes mellitus was induced in rats by streptozotocin and high-fat diet. Rats were treated with isorhamnetin (50 mg/kg/d) for 4 or 8 weeks. Fasting blood glucose, renal and lipid profiles were evaluated. Renal tissues were examined by light and electron microscopy. Autophagy genes ( FYCO1, ULK, TECPR1 and  WIPI2) and miR-15b, miR-34a and miR-633 were assessed by qRT-PCR, and LC3A/B by immunoblotting. Results: Isorhamnetin improved fasting blood glucose, renal and lipid profiles with increased autophagosomes in renal tissues. It suppressed miRNA regulation of autophagy genes Conclusion: We propose a molecular mechanism for the isorhamnetin renoprotective effect by modulation of autophagy epigenetic regulators.

scholarly journals Ameliorative Effect and Mechanism of the Purified Anthraquinone-Glycoside Preparation from Rheum Palmatum L. on Type 2 Diabetes Mellitus

Molecules ◽  
2019 ◽  
Vol 24 (8) ◽  
pp. 1454 ◽  
Author(s):  
Fang-Rong Cheng ◽  
Hong-Xin Cui ◽  
Ji-Li Fang ◽  
Ke Yuan ◽  
Ying Guo
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Cell Apoptosis ◽  
Fasting Blood Glucose ◽  
Β Cell ◽  
Diabetes Mellitus Group ◽  
Rheum Palmatum

Rheum palmatum L. is a traditional Chinese medicine with various pharmacological properties, including anti-inflammatory, antibacterial, and detoxification effects. In this study, the mechanism of the hypoglycemic effect of purified anthraquinone-Glycoside from Rheum palmatum L. (PAGR) in streptozotocin (STZ) and high-fat diet induced type 2 diabetes mellitus (T2DM) in rats was investigated. The rats were randomly divided into normal (NC), T2DM, metformin (Met), low, middle (Mid), and high (Hig) does of PAGR groups. After six weeks of continuous administration of PAGR, the serum indices and tissue protein expression were determined, and the pathological changes in liver, kidney, and pancreas tissues were observed. The results showed that compared with the type 2 diabetes mellitus group, the fasting blood glucose (FBG), total cholesterol (TC), and triglyceride (TG) levels in the serum of rats in the PAGR treatment groups were significantly decreased, while superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) levels were noticeably increased. The expression of Fas ligand (FasL), cytochrome C (Cyt-c), and caspase-3 in pancreatic tissue was obviously decreased, and the pathological damage to the liver, kidney, and pancreas was improved. These indicate that PAGR can reduce oxidative stress in rats with diabetes mellitus by improving blood lipid metabolism and enhancing their antioxidant capacity, thereby regulating the mitochondrial apoptotic pathway to inhibitβ-cell apoptosis and improve β-cell function. Furthermore, it can regulate Fas/FasL-mediated apoptosis signaling pathway to inhibit β-cell apoptosis, thereby lowering blood glucose levels and improving T2DM.

Disrupted circadian rhythms of body temperature, heart rate and fasting blood glucose in prediabetes and type 2 diabetes mellitus

2017 ◽  
Vol 34 (8) ◽  
pp. 1136-1148 ◽  
Author(s):  
D. G. Gubin ◽  
A. A. Nelaeva ◽  
A. E. Uzhakova ◽  
Y. V. Hasanova ◽  
G. Cornelissen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Heart Rate ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Body Temperature ◽  
Circadian Rhythms ◽  
Fasting Blood Glucose

scholarly journals Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus

2014 ◽  
Vol 37 (4) ◽  
pp. 243 ◽  
Author(s):  
Masahiro Ohira ◽  
Takashi Yamaguchi ◽  
Atsuhito Saiki ◽  
Noriko Ban ◽  
Hidetoshi Kawana ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Hypoglycemic Agents ◽  
Low Density

Purpose: Type 2 diabetes is known to be associated with increasing cardiovascular mortality. Malondialdehyde-modified LDL (MDA-LDL) is an oxidized LDL and is increased in patients with diabetes or hypertriglyceridemia. Elevated MDA-LDL has been reported to be a risk factor of atherosclerosis or cardiovascular disease. Sitagliptin is a dipeptidyl peptidase-4 inhibitor and a new class of hypoglycemic agents. In this study, the effects of increasing the dose of metformin and add-on sitagliptin on MDA-LDL were examined in type 2 diabetes patients. Methods: Seventy patients with type 2 diabetes, inadequately controlled despite on-going treatment with metformin 500 mg/day, were enrolled in this randomized controlled trial. The patients received additional metformin (500 mg/day) or sitagliptin (50 mg/day) for 6 months, and changes in metabolic parameters including MDA-LDL were evaluated. Results: After 6 months of treatment, add-on sitagliptin (n=35) improved fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) to significantly greater extent than increasing the dose of metformin (n=35). There were no differences in total cholesterol and low-density lipoprotein cholesterol levels between two groups. MDA-LDL levels (mean±S.E.) decreased significantly with increasing the dose of metformin (from 94.40±6.35 to 77.83±4.74 U/L, P < 0.005), but remained unchanged with add-on sitagliptin treatment (from 89.94±5.59 to 98.46±6.78 U/L, p > 0.05). Multiple linear regression analysis identified increasing the dose of metformin treatment as the only independent factor associated with decreased MDA-LDL (β coefficient 0.367, P < 0.0119), and no significant correlation between change in MDA-LDL and fasting blood glucose or HbA1c. Conclusion: These results suggest that increasing the dose of metformin improves serum MDA-LDL levels in type 2 diabetes mellitus.

scholarly journals PREVALENCE OF HYPOTHYROIDISM IN TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 3 (9) ◽  
Author(s):  
Dr. Harish Basera ◽  
Dr. K.C. Pant
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Fasting Blood Glucose ◽  
Family History Of Diabetes ◽  
Increased Risk

Introduction: Thyroid hormone deficiency can lead to adverse health effects even death, if left untreated. It is a pathological condition known as hypothyroidism. Most common symptoms of hypothyroidism in adults are weight gain, fatigue, lethargy, cold intolerance, constipation, and dry skin. These clinical presentations can differ with age and sex, among other factors. Thyroid Stimulating Hormone (TSH), is associated with an increased risk of developing a number of clinical conditions, like cardiovascular diseases, diabetes, lung disease, malignant condition, and psychiatric disorders, both before and after the diagnosis of thyroid dysfunction. Type 2 Diabetes Mellitus (T2DM) is the chronic endocrine disease which is characterized by hyperglycemia resulting in impaired insulin secretion insulin resistance. Material and Methods: This prospective observational study was carried out at OPD of Dept. of Medicine at Govt. Doon Medical College and Hospital. The study period was between jan2019 to August 2019. The anthropometric measurements and demographic characteristics of patients included in the study were recorded. The clinical details and medications are entered into Excel sheet of Microsoft Excel 2013. Biochemical tests were done and reports were entered. Results: Prevalence of hypothyroidism in T2DM is found to be 10.94% in our study. Average BMI was observed to be 28.01 kg/m2 with SD of 3.39 kg/m2. Level of T3 and T4 were observed to be 0.98(0.23) ng/ml and 1.24(0.29) ng/ml respectively. Fasting blood glucose level was 133.05(17.81) mg/dl and post prandial blood glucose level was 201.54(27.33) mg/dl. Among all 112 patients, 71(63.39%) of cases had a family history of diabetes. Conclusion: It is noted that one-tenth of patients with type 2 diabetes mellitus has hypothyroidism. BMI was noted to be more than 28 kg/m2 among all patients. Hypothyroidism may be prevalent in T2DM patients due to duration of diabetes, obesity. To confirm the findings, more studies in this area are required. Keywords: T2DM, Hypothyroidism, TSH, T3, T4.

scholarly journals Meditation Programs for Adults with Type 2 Diabetes Mellitus: Protocol for a Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Manxue Mei ◽  
◽  
Min Jiang ◽  
Zunjiang Li ◽  
Wei Zhu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Meta Analysis ◽  
Fasting Blood Glucose ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Review Question

Review question / Objective: Would meditation programs affect fasting blood glucose levels and HbA(1c) of patients with type 2 diabetes mellitus? Would meditation programs intervention be of benefit for remission of depression and anxiety level? Would meditation programs improve quality of life of individuals with type 2 diabetes？ Do meditation programs affect body mass index (BMI), serum lipid levels and level of blood pressure? Which type of meditation programs is better for type 2 diabetes patients? Are there any differences of efficacy among different meditation programs? To provide valid evidence for the effect of meditation programs for type 2 diabetes by synthesizing and comparing outcomes from clinical trials. Main outcome(s): The outcomes include fasting blood glucose levels and HbA(1c).

scholarly journals ASSOCIATION OF SERUM SIALIC ACID AND SERUM URIC ACID LEVELS WITH FASTING BLOOD GLUCOSE LEVELS IN TYPE-2 DIABETES MELLITUS PATIENTS

2020 ◽  
pp. 83-86
Author(s):  
YENDREMBAM PASCAL SINGH ◽  
VED PAL SINGH PUNIA ◽  
GLADYS RAI ◽  
MANOJ KUMAR NANDKEOLIAR
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Uric Acid ◽  
Blood Glucose ◽  
Sialic Acid ◽  
Serum Uric Acid ◽  
Fasting Blood Glucose ◽  
Serum Sialic Acid

Objectives: The objective of the study was to estimate the serum sialic acid and serum uric acid levels in patients with type-2 diabetes mellitus and non-diabetic individuals and determining the association of serum sialic acid and serum uric acid levels with fasting blood glucose levels in patients with type-2 diabetes mellitus and also in non-diabetic individuals. Methods: The study was a cross-sectional analysis where 70 individuals in the age group of 30–70 years participated during 6 months period. This included two groups, one for type-2 diabetes patients as cases and other non-diabetics as controls. In each group, 35 individuals participated. There were 15 males and 20 females in type-2 diabetic group and 16 males and 19 females in non-diabetic group. Fasting blood glucose, serum sialic acid, and serum uric acid were estimated in both the groups. Results: In this study, the serum sialic acid levels of type-2 diabetes mellitus were shown to be increased (76.60 ± 7.89) when compared to non-diabetics (39.66 ± 9.55) with a statistically significant, p < 0.001. The serum uric acid concentrations were also found to be slightly elevated in type-2 diabetes mellitus (4.48 ± 0.79) when compared to non-diabetics (4.28 ± 0.89) with a statistically non-significant, p = 0.323. Conclusion: Based on this study, it is concluded that serum sialic acid and serum uric acid levels have been found to be positively associated with type- 2 diabetes mellitus in both men and women, indicating the risk of developing microvascular complications in those patients. Therefore, estimating the sialic acid and uric acid levels can aid in the early diagnosis and prevention of microvascular complications caused by type-2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document